Introduction
The c-myc proto-oncogene belongs to a family of related genes implicated in the control of normal proliferation and the induction of neoplasia (Henriksson and Luscher, 1996) . Myc expression is activated by mitogenic signals (Kelly et al., 1983) and is suppressed by growth-inhibitory signals (Einat et al., 1985; Pietenpol et al., 1990; Alexandrow et al., 1995) , but is invariant in exponentially growing cells (Hann et al., 1985; Thompson et al., 1986) . Activation of c-myc is sucient to induce cell cycle entry in quiescent cells (Eilers et al., 1991) . Moreover, constitutive expression of c-myc inhibits dierentiation and prevents cells from leaving the cell cycle (Coppola and Cole, 1986; Freytag, 1988) . Conversely, inhibition of c-myc expression using an antisense approach leads to growth arrest and induction of dierentiation (Heikkila et al., 1987; Prochownik et al., 1988; Biro et al., 1993) .
The c-myc gene encodes a transcription factor of the helix ± loop ± helix-zipper class, which must dimerize with its partner Max, in order to bind DNA and transactivate from speci®c Myc sites (Blackwood and Eisenman, 1991; Kretzner et al., 1992) . The growthstimulatory activity of c-Myc depends on its ability to act as a transcription factor (Stone et al., 1987; Goruppi et al., 1994) . This suggests that Myc regulates the activation of genes involved in cell proliferation. Several genes have been identi®ed as direct c-Myc target genes, including ornithine decarboxylase, aprothymosin, cad, eIF-4E, eIF-2a, plasminogen activator inhibitor 1 and cdc25A (Prendergast et al., 1990; Eilers et al., 1991; Bello-Fernandez et al., 1993; Rosenwald et al., 1993; Miltenberger et al., 1995; Galaktionov et al., 1996) . However, with the possible exception of Cdc25A (Galaktionov et al., 1996) , none of these genes provide a good explanation how c-Myc exerts its strong eect on the cell cycle.
A frequent event during the process of cellular dierentiation is a reduction in c-Myc protein levels and a concomitant increase in Mad or Mxi proteins Larsson et al., 1994; Hurlin et al., 1995a,b) . Mad and Mxi proteins also interact with Max and Mad:Max and Mxi:Max heterodimers bind to the same CACGTG Myc:Max recognition sites. However, Mad:Max and Mxi:Max heterodimers repress transcription by ternary complex formation with the mammalian homologue of the yeast repressor SIN 3 Ayer et al., , 1995 Zervos et al., 1993; Schreiber-Agus et al., 1995) , reviewed by Bernards (1995) . Indeed, when Mad is ectopically expressed in exponentially growing cells, an inhibition of cell proliferation is observed VaÈ strik et al., 1995) and cells accumulate in the G 1 phase of the cell cycle (Roussel et al., 1996) . Consistent with opposing activities of Myc and Mad family proteins, expression of Mad inhibits Mycmediated transformation (Lahoz et al., 1994; Cerni et al., 1995; Koskinen et al., 1995; Schreiber-Agus et al., 1995) and mediates repression of c-Myc target genes (Wu et al., 1996) .
Progression through the cell cycle depends on the activation of cyclin dependent kinases (CDKs) and their regulatory subunits, the cyclins (reviewed by Sherr, 1996) . To pass the restriction point in late G 1 , which commits the cells to complete a mitotic division cycle, the activities of cyclin D/CDK4 (or CDK6) and cyclin E/CDK2 are required to hyperphosphorylate and thereby inactivate the retinoblastoma protein, pRb (see Beijersbergen and Bernards, 1996 for a review). The pRb family proteins p107 and p130 are also CDK substrates (Beijersbergen et al., 1995; Mayol et al., 1996) . Hypophosphorylated pRb family proteins bind to and inactivate members of the E2F/DP family of transcription factors. The E2F/DP family members positively activate genes whose products are required for cell cycle progression (Beijersbergen and Bernards, 1996) .
The activity of CDK complexes depend of their expression levels, association with cyclins, phosphorylation status and the association with speci®c CDKinhibitors (CKIs) (Sherr, 1993; Sherr and Roberts, 1995) . The critical role of cyclin/CDK complexes in G 1 -S progression make them plausible candidates to be regulated by c-Myc. Previous studies on the role of cMyc in the transcriptional regulation of cyclins appear sometimes inconsistent. For example, A-type cyclin and E-type cyclin transcription is enhanced (strongly versus moderately) in response to c-Myc (Jansen-Durr et al., 1993) , whereas no signi®cant changes were observed in the amounts of cyclin E and D1 in other reports (Hermeking et al., 1995; Steiner et al., 1995; Vlach et al., 1996) . Furthermore, it seems that the c-Myc eects on D-type cyclins are cell type-dependent (Jansen-Durr et al., 1993; Solomon et al., 1995; Marhin et al., 1996) . Nevertheless, several recent studies indicate that activation of c-myc causes a rapid induction of G 1 cyclin/CDK kinase activity (Steiner et al., 1995; Vlach et al., 1996) , indicating that c-Myc indeed targets the G 1 cyclin/CDK complexes. However, the precise mechanism by which Myc acts to control cyclin/CDK complex activity is still unclear.
In this work, we have further studied cell cycle targets of c-Myc. We show that inactivation of Myc activity in exponentially growing cells causes cells to arrest in G 1 as a result of a defect in cyclin E/CDK2 kinase activity.
Results

MadMyc expression causes exponentially growing NIH3T3 cells to arrest in G 1
To ask which components of the cell cycle machinery are targets of c-Myc, we constructed a strong antagonist of c-Myc activity. Even though it is wellestablished that Mad:Max and Myc:Max complexes can bind to the same CACGTG motif in transient transfection experiments, it is not clear whether under physiological conditions Myc:Max and Mad:Max heterodimers also bind to exactly the same sites. Therefore, to create a strong repressor of c-Mycresponsive transcription, we removed the amino terminal transactivation domain of c-Myc and replaced it with the amino terminal transcriptional repression domain of Mad, thus generating MadMyc (Figure 1a ). This chimeric protein contains the complete DNA binding and dimerization domains of c-Myc. It is therefore likely that MadMyc will bind to the same sites in the genome that are normally occupied by wild type c-Myc, thereby causing active repression of c-Myc-responsive genes.
To study the eect of MadMyc on cell cycle, we cotransfected exponentially growing NIH3T3 cells with the MadMyc expression vector and a CD20 expression vector. After 48 h, transfected cells were detected bȳ ow cytometry with anti CD20 antibody. Cell cycle distribution was measured by propidium iodide staining of DNA as described (Beijersbergen et al., 1995) . (Table 1a) .
To test whether the growth-inhibitory function of MadMyc depended on speci®c DNA binding and on the presence of the Mad repression domain, two additional mutants were generated; DNMyc lacks the Mad repression domain, MadMycDC lacks the DNAbinding/heterodimerization domain (Figure 1a ). Indeed, both mutants (both of which were expressed at high levels, Figure 1c ) failed to induce a signi®cant G 1 arrest and did not suppress colony outgrowth as eciently as MadMyc (Table 1a ,b). These observations indicate that sequence-speci®c DNA binding and transcriptional repression by MadMyc are required to cause a G 1 cell cycle arrest.
MadMyc antagonizes c-Myc
To test whether MadMyc causes repression of a bona ®de c-myc target gene, ornithine decarboxylase (BelloFernandez et al., 1993) , we used a reporter plasmid that carries the ornithine decarboxylase promoter and ®rst intron (that harbors the c-Myc binding sites) linked in frame in exon 2 to chloramphenicol acetyl transferase (CAT). Figure 2 Transcription-repression by MadMyc of the ODC-CAT promoter, NIH3T3 cells were transfected with the ODC-CAT reporter alone or co-transfected with reporter plasmid and pJ3-cmyc (5 mg) together with increasing amounts of the MadMyc expression vector. Cells were harvested 48 h after transfection, and cells extracts were analysed for CAT activity as described. pCMV-luciferase was included as an internal control. CAT activities were corrected with the internal control and the basal activity of the reporter was arbitrarily set at one of c-Myc expression vectors as too high a level of cMyc induces apoptosis (Evan et al., 1992) . Note that the c-Myc expression vector used in this experiment (pCMV-Myc) diers from the vector used in the ODC-CAT experiment (pJ3-Myc, driven by the SV40 early promoter). These data support the notion that MadMyc inhibits cell cycle progression through inhibition of wild type c-Myc function.
MadMyc induces G 1 arrest by targeting G 1 cyclin/kinase complexes
It has recently been shown that c-Myc activates the expression of Cdc25A, a gene that plays a role in the G 1 phase of the cell cycle (Galaktionov et al., 1996) . To test whether suppression of Cdc25A is responsible for the MadMyc-induced G 1 arrest, we co-transfected MadMyc and Cdc25A expression vectors and analysed cell cycle distribution. Figure 3b shows that Cdc25A (which was expressed at elevated levels in transfected cells, Figure 3d ) did not rescue the MadMyc-induced G 1 increase, indicating that MadMyc does not inhibit cell cycle progression primarily by suppression of Cdc25A expression. Previous studies have shown that induction of c-Myc in quiescent cells activates G 1 speci®c cyclin/kinase complexes by as yet unknown mechanism(s) (Steiner et al., 1995; Rudolph et al., 1996) . To investigate whether the MadMyc-induced G 1 arrest involves repression of the activity of G 1 cyclin/CDK complexes, we tested the ability of MadMyc to cause G 1 arrest in the presence of ectopically expressed cyclin E/CDK2 or cyclin D1/ CDK4 complexes. Figure 3c shows that co-expression of both cyclin E/CDK2 and cyclin D1/CDK4 To study further the eect of MadMyc on G 1 cyclin/ kinase complexes, we measured the phosphorylation status of the G 1 cyclin/CDK substrates pRb and p107 in MadMyc-arrested cells. We co-transfected pRb or p107 with MadMyc and analysed the phosphorylation status of the pocket proteins by Western analysis. We observed a signi®cant accumulation of both hypophosphorylated pRb and p107 when MadMyc was coexpressed ( Figure 4a) . Furthermore, when either cyclin E/CDK2 or cyclin D1/CDK4 was co-expressed with MadMyc, a complete reversal of the MadMyc-induced pRb hypophosphorylation was seen (Figure 4b) . We conclude from these data that the lack of pRb phosphorylation in MadMyc-transfected cells is the result of a reduced G 1 cyclin/CDK kinase activity in these cells. Taken together, these data provide strong evidence that MadMyc-induced G 1 arrest is the result of a speci®c reduction in G 1 cyclin/CDK complex activity.
MadMyc -induced cell cycle G 1 arrest is independent of pRb
Next we asked whether the accumulation of hypophosphorylated pRb is responsible for the observed G 1 arrest in MadMyc-transfected cells. To test this, we transfected pRb 7/7 3T3 cells with MadMyc expression vector and measured its eect on cell cycle distribution. Table 2a shows that MadMyc also induced a signi®cant increase in G 1 cells in the pRb 7/7 cells. Similarly, stable expression of MadMyc suppressed colony outgrowth in cells lacking functional pRb (Table 2b ). These data show that accumulation of hypophosphorylated pRb is not primarily responsible for the observed MadMyc G 1 arrest, which suggests the involvement of other cell cycle targets in the G 1 arrest.
Rescue of MadMyc cell cycle arrest by kinase-inactive G 1 cyclin complexes
It is well-established that pRb 7/7 cells do not require cyclin D1/CDK4 kinase activity to progress through a cell cycle (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995) . Since the pRb 7/7 3T3 cells were still sensitive to a MadMyc-induced G 1 arrest (Table 2a ,b) it is likely that cyclin D-associated kinase activity is not a crucial target of MadMyc. Nevertheless, we did observe a complete reversal of the MadMyc induced G 1 increase upon ectopic expression of cyclin D1/CDK4 ( Figure  3c ). To study this apparent contradiction in more detail, we co-transfected MadMyc and cyclin D1 in the presence of increasing concentrations of a dominant negative mutant of CDK4 (CDK4-DN). We measured the activity of cyclin D-associated kinase activity in transfected cells by monitoring the phosphorylation status of p107 in transfected cells. Since p107 is phosphorylated only by cyclin D/CDK4 and not by other G 1 cyclin/kinase complexes (Beijersbergen et al., 1995) , phosphorylation of p107 is a good indicator of cyclin D1/CDK4 kinase activity in transfected cells. A. Rb 7/7 3T3 cells were transfected with 4 mg pCMV-CD20 together with control vector or 2, 5 or 15 mg of pCMV-MadMyc. The cell cycle pro®le of CD20-positive cells and the percentage of cells in each stage were determined by FACS and the computer program Mod®t. The percentages of cells in each stage were obtained from three independent experiments and are depicted in panel A. B. A colony formation assay was performed as described in Table 1A Cell cycle targets of c-Myc K Berns et al Figure 5b shows that at increasing concentrations of cotransfected CDK4-DN, the phosphorylation of p107 decreased. At the highest concentration of CDK4-DN, p107 was almost completely hypophosphorylated, indicating that in these cells CDK4-DN inactivated most if not all the ectopically expressed cyclin D1. Nevertheless, in these cells, cyclin D1/CDK4-DN expression completely reversed the cell cycle-inhibitory eect of MadMyc (Figure 5a ). These data indicate that the cyclin D1/CDK4 complex does not require kinase activity to rescue the MadMyc G 1 arrest.
MadMyc-arrested cells have reduced E-associated kinase activity
The data shown above are compatible with a model in which MadMyc acts primarily to inhibit the activity of the cyclin E/CDK2 kinase complex. To test this, we cotransfected CD20 and MadMyc expression vectors in NIH3T3 cells, or with CD20 vector alone as a control. After 2 days, cells were stained with FITC-labeled CD20 antibody and transfected cells were collected using a Fluorescent Activated Cell Sorter (FACS). Flow sorted cells were analysed for the expression levels of G 1 -cyclins, CDKs and CKIs by Western analysis. Figure 6a shows that MadMyc expression has no eect on expression levels of CDK4, CDK2, cyclin D1, cyclin E or p27 kip1 , ®ve cell cycle proteins involved in G 1 regulation. To test whether under these experimental conditions MadMyc aected the activity of cyclin E/CDK2 complexes, we performed a cyclin Eassociated kinase assay on FACS-sorted cells. Figure  6b shows that expression of MadMyc resulted in a signi®cant decrease in cyclin E-associated kinase activity (on average ®vefold in three independent experiments). We conclude from this that MadMyc causes an arrest in G 1 cell cycle progression by inhibiting cyclin E-associated kinase activity without altering the expression levels or cyclin E, CDK2 or p27 kip1 .
Discussion
MadMyc induces growth arrest
We (Figure 1b) . In addition, stable expression of MadMyc prevented colony outgrowth of transfected cells (Table 1) . Two lines of evidence indicate that this growth-inhibitory activity of MadMyc is the result of its ability to antagonize c-Myc function. First, mutants of MadMyc that lacked either the C-terminal DNA binding domain or the N-terminal Mad repression domain failed to cause an ecient G 1 arrest (Table 1) . Second, inhibition of cell cycle progression by MadMyc was overruled by co-expression of wild type c-Myc, suggesting that MadMyc 
Mechanism of MadMyc growth arrest
MadMyc growth-arrested cells have hypophosphorylated pRb and p107, suggesting that the growth arrest is the consequence of a defect in G 1 cyclin/CDK kinase activity. Indeed, when we co-transfected MadMyc together with either cyclin E/CDK2 or cyclin D1/ CDK4, we observed a complete reversal of the MadMyc G 1 arrest (Figure 3c ). The transient transfection procedure used here did not allow the direct determination of the activity of cyclin D/CDK kinase complexes, as not enough transiently transfected cells can be selected by¯ow sorting to allow detection of cyclin D-associated kinase activity. Nevertheless, several lines of evidence indicate that although cyclin D/CDK4 activity may be aected by MadMyc, it is not the primary target of MadMyc. First, the MadMyc-induced cell cycle arrest was independent of the presence of a functional pRb protein, as pRb 7/7 3T3 cells were also arrested by MadMyc (Table 2) . Since pRb 7/7 cells do not require cyclin D/ CDK4 activity (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995) , it is unlikely that cyclin Dassociated kinase activity is the primary target of MadMyc. That agents that do target cyclin Dassociated kinase activity directly cause a pRbdependent G 1 arrest was recently shown. A dominant-negative allele of Ha-ras, which speci®cally inhibits cyclin D1-associated kinase activity, can cause G 1 arrest in asynchronously growing 3T3 cells, but not pRb 7/7 3T3 cells (Peeper et al., 1997) . Second, expression of a kinase-inactive cyclin D1/CDK4 complex also rescued the MadMyc-induced growth arrest, indicating that the kinase activity of the complex is irrelevant for the rescue of the MadMyc G 1 arrest ( Figure 5) . Third, experiments which investigated signal transduction through the CSF-1 receptor suggested that c-Myc and cyclin D crossregulate each other's expression, and do not function in a linear signaling pathway (Roussel et al., 1995) . Furthermore, cyclin D can cooperate with c-Myc to induce B cell lymphomas in transgenic mice (Bodrug et al., 1994) . Taken together, these data favor a model in which c-Myc and cyclin D cooperate in parallel pathways rather than in a linear pathway.
The rescue of the MadMyc G 1 arrest by cyclin E/ CDK2 complexes raised the possibility that MadMyc aects the activity of cyclin E/CDK2 kinase. When we measured cyclin E-associated kinase activity we could indeed show a signi®cant reduction in cyclin Eassociated kinase activity in MadMyc-transfected cells (Figure 6 ). Interestingly, MadMyc did not aect the expression levels of cyclin E, CDK2 or the CKI p27, suggesting an indirect eect of MadMyc on the cyclin E/CDK2 kinase complex. Recent evidence indicate that the CDK-activating enzyme Cdc25A is an important target of Myc during cell cycle entry (Galaktionov et al., 1996) . Reduction of Cdc25A expression by MadMyc and subsequent decrease in CDK2 activating activity may therefore account for the observed reduction in cyclin E/CDK2 kinase activity. However, we could not show a rescue of the MadMyc G 1 arrest by co-expression of Cdc25A expression vector that directs the synthesis of high levels of Cdc25A protein (Galaktionov et al., 1995) (Figure 3b,d) . Furthermore, ectopically expressed cyclin E/CDK2 kinase is active in MadMyc-expressing cells, suggesting that Cdc25A is not limiting for activation of cyclin E/CDK2 in these cells (Figure 4b ). Taken together, these data indicate that in cycling cells repression of c-Myc activity does not cause G 1 arrest primarily by depleting cells of Cdc25A. Consistent with this, activation of c-Myc in quiescent cells in vivo leads to only a partial activation of cyclin E/CDK2 complexes, which could be further activated by incubation with Cdc25A in vitro. (Steiner et al., 1995) . Thus, activation of c-Myc alone is not sucient to give full activation of Cdc25A, whereas inhibition of c-Myc does not appear to lead to a complete shut-o of Cdc25A activity.
Even though cyclin E/CDK2 eciently rescued a MadMyc-induced G 1 arrest in transient transfection (7) or 15 mg pCMVMadMyc (MM). Transfected cells were selected on a FACS sorter, lysed, and cell extracts were subjected to SDS ± PAGE. The separated proteins were transferred to nitrocellulose and were detected by Western analysis. (b) The same cell lysates that were analysed by Western were used in a cyclin E-associated kinase assay in which Histone H1 was used as a substrate.
experiments, our recent data indicate that MadMyc mediated inhibition of colony outgrowth (Tables 1 and  2) is not rescued by co-expression of cyclin E/CDK2 (K Berns and R Bernards, unpublished data). This indicates that, even though the immediate eects of MadMyc on cell cycle are mediated through cyclin E/ CDK2, the long-term eects of MadMyc may involve multiple cellular targets, which do not become limiting in a short term transient transfection assay. Such additional targets that are aected by MadMyc in long term assays may include established c-Myc targets such as ornithine decarboxylase and Cdc25A. Several other studies have recently provided independent evidence that c-Myc regulates the activity of the cyclin E/CDK2 kinase complex. Steiner et al., showed that activation of c-Myc in quiescent cells induced the activation of cyclin E-dependent kinases without signi®cant changes in the amount of cyclin E/CDK2 complex. Activation of c-Myc resulted in a release of inactive cyclin E/CDK2 from a high molecular weight complex in lower molecular weight active complex (Steiner et al., 1995) . More recent data indicate that cMyc liberates cyclin E/CDK2 from inactive p27-containing complexes and it has been suggested that cMyc acts by inducing sequestration of p27 away from cyclin E/CDK2 by a non-covalent interaction (Vlach et al., 1996) . Similarly, it has been suggested that c-Myc overcomes a p53 G 1 arrest by sequestering p21 (Hermeking et al., 1995) . In view of these data we speculate that the reduced cyclin E/CDK2 activity observed in MadMyc-arrested cells may be due to a decreased expression of an inhibitor of CKIs. Our data are consistent with the`seqestration-of-CDK-inhibitor' model in that we show that kinase-inactive cyclin D1/ CDK4 complexes, which have retained the ability to sequester CKIs, can also release cells from a MadMyc induced G 1 arrest. That cyclin D/CDK4 complexes can indeed act to sequester CKIs such as p27 away from cyclin E/CDK2 has recently been demonstrated (Polyak et al., 1994) . The elucidation of the precise defect in cyclin E/CDK2 kinase activity described here requires biochemical experiments involving rather large numbers of cells which cannot be obtained from transiently transfected cells selected by¯ow sorting. Therefore, future research will focus on the study of MadMyc targets in other systems.
Materials and methods
Cell lines
NIH 3T3 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% newborn calf serum. pRb 7/7 3T3 cells (Zalvide and DeCaprio, 1995) were cultured in DMEM in the presence of 10% fetal calf serum. Transfections were performed using the calcium phosphate precipitation technique (Van der Eb and Graham, 1980) .
Plasmids
The sequence coding for c-Myc was excised from pJ3-myc (Beijersbergen et al., 1994a) and cloned in pRc/CMV. For pCMVMadMyc, the N-terminal c-Myc coding region (amino acids 1 ± 263) in pCMVc-myc was removed via a HindIII/ClaI digestion and replaced by a cDNA fragment encoding amino acids 1 ± 38 of human Mad. The amino acid 1 ± 38 Mad fragment was made by PCR using pJ3-Mad as a template. pCMVDNMyc was made by PCR using pCMVc-myc as a template, it encodes c-myc amino acids 263 ± 440. pCMVMadMycDC was constructed by PCR with a 5'mad primer and a 3'c-myc primer (at the position of amino acid 355) using pCMVMadMyc as a template. The mad(1 ± 38)myc(263 ± 355) fusion was cloned into a pcDNA3 vector containing a myc monoclonal antibody 9E10-tag at the 3'end, enabling detection of MadMycDC protein with the 9E10 antibody. The plasmids pCMV-Rb, pCMV-107HA, pCMVCD20, pCMV-p27, pCMV-cyclin E, cyclin D, CDK2 and CDK4 were described previously (Beijersbergen et al., 1994b (Beijersbergen et al., . 1995 . pODC-CAT (kindly donated by Dr H van Steeg, RIVM, Bilthoven, The Netherlands) is a reporter plasmid containing 787 base pairs of the 5' regulatory region of the human ODC gene, linked to exon 1 and intron 1 and part of exon 2 (78 bp), fused to CAT. pCMV-cdc25A was generated by cloning the coding sequence from human cdc25A (kind gift of Dr B Amati) in pRc/CMV.
Antibodies
The following antibodies for detection in Western were used: against human pRb: C15 (Santa Cruz, sc); p107HA: 12CA5 (directed against HA epitope); MadMyc, DNMyc, MadMycDC: 9E10 (Evan and Hancock, 1985) ; cyclin D: anti-human D1 (UBI); cyclin E; M20 (sc); p27: C19 (sc) or K25020 (Transduction Laboratories); CDK2: M2 (sc); CDK4: C22 (sc). Ccd25A was immunoprecipitated with a c-terminal peptide antibody. Western blot analysis was done using antibodies against the Gst-Cdc25A fusion protein (kind gifts of Dr K Galaktionov). For the IPkinase assays described here we used M20 (sc) for the cyclin E immunoprecipitations.
Cell cycle analysis
NIH3T3 cells were transfected using the calcium phosphate precipitation technique. After 16 h the cells were washed twice with DMEM/10% NCS. Twenty-four hours after transfection, nocodazole (50 ng/ml) was added and the cells were incubated for another 16 h at 378C. The cells were harvested, washed with PHB (PBS, 20 mM HEPES, 0.1% BSA) and stained with 20 ml of FITC conjugated anti CD20 monoclonal antibody (Becton-Dickinson) for 1 h on ice. The cells were washed and ®xed in 70% ethanol at 48C. Before FACS analysis, the cells were washed with PHN (PBS, 20 mM HEPES, 0.5% NP-40), and incubated with 10 mg/ml propidium iodide and 250 mg/ml RNAse A. The FACS analysis was performed on a Becton-Dickinson FACScan¯ow cytometer. DNA content histograms of cells expressing transfected genes were obtained by selecting CD20-positive cells with a¯uorescent intensity greater than the background level. The percentages of cells within the dierent phases of the cell cycle were determined with the computer program ModFit.
CAT assays
NIH3T3 cells were transfected with the expression vectors as indicated together with 4 mg pODC-CAT and 1.0 mg pCMV-luciferase. pRc/CMV was added to a total of 20 mg DNA per 100 mm dish. Cells were harvested 40 h after transfection and resuspended in 100 ml 0.1 M Tris-HCL. Cells were freeze/thawed three times and centrifuged at 4000 g for 10 min. Supernatants were assayed for CAT activity using the phase extraction method and luciferase activity (Promega, Luciferase system). CAT activity was normalised to luciferase activity.
Western blot analysis
Cells were lysed in SDS-containing sample buer. The cell extracts were separated on SDS-polyacrylamide gels and transferred to nitrocellulose and blocked in PBS/0.05% Tween-20/ 5% dried milk for 2 h at room temperature. The membrane was incubated with antibody diluted in PBS/ 0.05% Tween-20/ 1% dried milk for 16 h at 48C. After washing the membrane, the antibody was detected using horseradish peroxidase-linked goat or mouse IgG and enhanced chemiluminescence (ECL, Amersham). MadMyc, DNMyc and MadMycDC were detected with 9E10 at 1:10 dilution, cyclin E with M20 in 1:500 dilution, cyclin D with anti-human D in 1:2000 dilution, human Rb with C15 in 1:4000 dilution, p107HA with 12CA5 in 1:10 dilution, p27 with C19 or K25020 in 1:500 dilution, CDK2 with M2 in 1:2000 dilution, CDK4 with C22 in 1:2000 dilution.
Cdc25A was detected in an immunoprecipitation/Western blotting experiment as described (Galaktionov et al., 1996) .
Immune-complex kinase assays
Empty vector or pCMV-MadMyc together with pCMV-CD20 were transfected into NIH3T3 cells. After 16 h, the cells were washed and 40 h after transfection the cells were harvested, washed and stained with FITC conjugated anti CD20 monoclonal antibody. CD20-positive cells were selected on a FACS sorter. Selected cells were used to perform cyclin E immunoprecipitations and analysis of cyclin E-dependent kinase according to (Dulic et al., 1992) using the anti-cyclin E (M20) antibody and histone H1 as a substrate. Parallel cell lysates were used for Western blot analysis.
